Ascentage Pharma saw its share price surge 57% during the first day of trading in Hong Kong before closing up 9.9%, following a heavily oversubscribed HK$416.6 million ($53 million) IPO.
The Chinese drug developer sold 12.18 million shares for HK$34.20 apiece, according to a filing. The Hong Kong portion of the offering was enlarged after subscriptions exceeded the available volume of...
Sequoia Capital closed its latest set of funds for deployment in India and Southeast Asia with $1.35 billion in commitments.
Ucommune, a Chinese co-working space operator that failed to get traction with an attempted New York IPO last year, has been acquired by a US-listed special purpose acquisition company (SPAC) at a valuation of $764.9 million.
Indies Capital, a Singapore-based GP focused on Indonesia, has reached a first close of $100 million for its third flagship private equity and credit fund.
EQT has submitted a revised offer to acquire New Zealand retirement village player Metlifecare at a lower valuation after facing a legal challenge over its attempt to terminate a previously agreed deal.